Sanofi completes acquisition of Vigil Neuroscience
Sanofi has completed its acquisition of Vigil Neuroscience, adding VG-3927, a novel, oral, small-molecule TREM2 agonist, to Sanofi’s neurology pipeline.
Vigil is a clinical-stage biotechnology company targeting neurodegenerative diseases through disease-modifying therapeutics that restore the vigilance of microglia.
Sanofi will also acquire Vigil’s preclinical pipeline in various neurodegenerative diseases, but did not acquire VGL101, Vigil’s second clinical programme.
In June 2024, Sanofi made a $40 million strategic investment in Vigil that included the exclusive right of first negotiation for an exclusive license, grant, or transfer of rights to research, develop, manufacture, and commercialise VG-3927.
Sanofi has acquired all outstanding common shares of Vigil for $8 per share in cash at closing, representing an equity value of approximately $470 million.
In addition, Vigil’s shareholders received a non-transferrable contingent value right (CVR) per Vigil share, which entitles its holder to receive a deferred cash payment of $2, conditioned upon the first commercial sale of VG-3927.
VG-3927 is poised to enter a Phase II clinical study in patients with Alzheimer’s disease.
Vigil says genome wide association studies (GWAS) have shown that a specific mutation in a TREM2 variant (R47H) is one of the strongest genetic risk factors for AD, second in magnitude only to that associated with the apolipoprotein E4 (ApoE4) genotype. Recent studies have shown that increased TREM2 expression is protective against AD.
TREM2 is the key receptor that senses the presence of multiple ligands that indicate trouble – including Aβ and ApoE. When these ligands are elevated, they bind to TREM2, triggering changes in microglia so they can remove the damage or pathologic aggregates and debris.
By activating TREM2 with an agonist, the company aims to enhance the natural neuroprotective function of microglia in AD, boosting their ability to neutralise multiple causes of AD pathology.
Diana Turner, Senior Digital Content Editor, DDW
